The Current Ratio as of November 2024 (TTM) for Emmaus Life Sciences, Inc. (EMMA) is 0.14

According to Emmaus Life Sciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.14. This represents a change of -3.85% compared to the average of 0.15 of the last 4 quarters.

Emmaus Life Sciences, Inc. (EMMA) Historical Current Ratio (quarterly & annually)

How has EMMA Current Ratio performed in the past?

The mean historical Current Ratio of Emmaus Life Sciences, Inc. over the last ten years is 1.08. The current 0.14 Current Ratio has changed 1.23% with respect to the historical average. Over the past ten years (40 quarters), EMMA's Current Ratio was at its highest in in the September 2017 quarter at 3.68. The Current Ratio was at its lowest in in the June 2015 quarter at 0.06.

Emmaus Life Sciences, Inc. (EMMA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Emmaus Life Sciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Emmaus Life Sciences, Inc. (EMMA) Average Current Ratio

How has EMMA Current Ratio performed in the past?

The current Current Ratio of Emmaus Life Sciences, Inc. (EMMA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Emmaus Life Sciences, Inc. (EMMA) Current Ratio vs. Peers

How is EMMA’s Current Ratio compared to its peers?

Emmaus Life Sciences, Inc.’s Current Ratio is less than NRx Pharmaceuticals, Inc. (0.20), greater than Kaleido Biosciences, Inc. (0), less than Applied Molecular Transport Inc. (4.99), greater than Scopus BioPharma Inc. (0.05), less than Cell Source, Inc. (0), greater than Adhera Therapeutics, Inc. (0.01), greater than PolarityTE, Inc. (0.00), less than ZIVO Bioscience, Inc. (6.41), less than Anebulo Pharmaceuticals, Inc. (0.17), less than Adagene Inc. (3.45), less than Acrivon Therapeutics, Inc. Common Stock (2.50), less than AnaptysBio, Inc. (12.75), less than Mineralys Therapeutics, Inc. (10.23), less than null (8.55),

Build a custom stock screener for Emmaus Life Sciences, Inc. (EMMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Emmaus Life Sciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Emmaus Life Sciences, Inc. (EMMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Emmaus Life Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.